{
    "clinical_study": {
        "@rank": "120854", 
        "arm_group": [
            {
                "arm_group_label": "2HRZE/4HR", 
                "arm_group_type": "Experimental", 
                "description": "Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months"
            }, 
            {
                "arm_group_label": "2HRLE/4HR", 
                "arm_group_type": "Active Comparator", 
                "description": "Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months"
            }, 
            {
                "arm_group_label": "9HLE", 
                "arm_group_type": "Experimental", 
                "description": "Isoniazid+ Levofloxacin+ Ethambutol for 9 months"
            }, 
            {
                "arm_group_label": "9RLE", 
                "arm_group_type": "Active Comparator", 
                "description": "Rifampicin + Levofloxacin+ Ethambutol for 9 months"
            }
        ], 
        "brief_summary": {
            "textblock": "During the Study:\n\n        -  Subject is required to visit every week for the first 2 months and then every month\n           till completion of study or as and when required\n\n        -  The usual symptomatic and supportive treatment of Chronic Liver Disease, including use\n           of antiviral, will be given to all patients.\n\n        -  Effort will be made to avoid use of other hepatotoxic drug(s) during Anti-Tubercular\n           Treatment.\n\n        -  Liver function tests (LFT) will be done weekly during first 2 months then at one month\n           interval or as when required.\n\n        -  The treatment efficacy of Anti-Tubercular Treatment (ATT) will be made on the basis of\n           clinical, biochemical, microbiological and imaging parameters at months 2, 4, 7 and 9.\n           Patients not improving at 4 weeks after initiation of treatment will be shifted to\n           alternative regimens and will be excluded from the study."
        }, 
        "brief_title": "Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Chronic Liver Disease With Tuberclosis", 
        "condition_browse": {
            "mesh_term": [
                "Liver Diseases", 
                "Tuberculosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or Females subjects aged 18-75 years.\n\n          -  Subjects with chronic liver disease (cirrhosis)\n\n          -  Pulmonary or extra-pulmonary tuberculosis.\n\n          -  Serum ALT\u22645times upper limit and serum bilirubin \u22643 mg/dl.\n\n          -  consent and willingness to follow-up\n\n        Exclusion Criteria:\n\n          -  Serum ALT>5times upper limit and serum bilirubin >3 mg/dl.\n\n          -  Renal failure (serum creatinine>2mg/dl).\n\n          -  Presence of hepatocellular carcinoma\n\n          -  Alcoholic cirrhotic who continue to drink alcohol.\n\n          -  Prior history of ATT (ANTI TUBERCULAR TREATMENT) with documented hepatotoxicity.\n\n          -  Known hypersensitivity to levofloxacin, other quinolones"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01677871", 
            "org_study_id": "ILBS-ATT-01"
        }, 
        "intervention": [
            {
                "arm_group_label": "2HRLE/4HR", 
                "description": "Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months", 
                "intervention_name": "2HRZE/4HR", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "2HRZE/4HR", 
                "description": "Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months", 
                "intervention_name": "2HRLE/4HR", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "9RLE", 
                "description": "Isoniazid+ Levofloxacin+ Ethambutol for 9 months", 
                "intervention_name": "9HLE", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "9HLE", 
                "description": "Rifampicin + Levofloxacin+ Ethambutol for 9 months", 
                "intervention_name": "9RLE", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antitubercular Agents", 
                "Ethambutol", 
                "Isoniazid", 
                "Rifampin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 16, 2013", 
        "location": {
            "contact": {
                "email": "bhardwaj.ankit3@gmail.com", 
                "last_name": "Dr Ankit Bhardwaj", 
                "phone": "011-46300000"
            }, 
            "contact_backup": {
                "email": "bhardwaj.ankit3@gmail.com", 
                "last_name": "Dr Ankit Bhardwaj", 
                "phone": "011-46300000", 
                "phone_ext": "1032"
            }, 
            "facility": {
                "address": {
                    "city": "New Delhi", 
                    "country": "India", 
                    "state": "Delhi", 
                    "zip": "110070"
                }, 
                "name": "Institute of Liver and Biliary Sciences"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "India"
        }, 
        "number_of_arms": "4", 
        "official_title": "Study of Efficacy and Safety of Modified Anti-tubercular Regimens in Treatment of Tuberculosis in Patients With Underlying Compensated and Decompensated Chronic Liver Disease", 
        "overall_contact": {
            "email": "naveenilbsdelhi@gmail.com", 
            "last_name": "Dr Naveen Kumar, MD", 
            "phone": "011-46300000"
        }, 
        "overall_contact_backup": {
            "email": "bhardwaj.ankit3@gmail.com", 
            "last_name": "Dr Ankit Bhardwaj", 
            "phone": "011-46300000", 
            "phone_ext": "1032"
        }, 
        "overall_official": {
            "affiliation": "Institute of Liver and Biliary Sciences", 
            "last_name": "Dr Naveen Kumar, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "India: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Successful completion of modified ATT (ANTI TUBERCULAR TREATMENT) regimen.", 
            "safety_issue": "No", 
            "time_frame": "6 and 9 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01677871"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Worsening of CTP (CHILD TURCOTTE PUGH) score to \u226510 for patients with compensated cirrhosis,", 
                "safety_issue": "No", 
                "time_frame": "6 and 9 months"
            }, 
            {
                "measure": "Failure to re-institute the assigned ATT (ANTI TUBERCULAR TREATMENT) regimen after development of an episode of hepatotoxicity. (I.e. second episode of hepatotoxicity.", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Survival", 
                "safety_issue": "No", 
                "time_frame": "6 and 9 months"
            }
        ], 
        "source": "Institute of Liver and Biliary Sciences, India", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Institute of Liver and Biliary Sciences, India", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}